In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia.
Ann Intern Med
; 175(9): JC104, 2022 09.
Article
en En
| MEDLINE
| ID: mdl-36063558
ABSTRACT
SOURCE CITATION Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;1451460-70. 35394821.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
/
Hiperpotasemia
/
Hipopotasemia
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Ann Intern Med
Año:
2022
Tipo del documento:
Article